Search Results (3)

Background/Objectives: Migraine and diabetes mellitus are highly prevalent chronic diseases, and their comorbidity presents management challenges, particularly when wearable medical technologies are used concurrently. Remote electrical neuromodulation (REN; Nerivio^®) is an FDA-cleared non-pharmacological migraine therapy, and continuous glucose monitoring (CGM) systems are widely used in diabetes care. However, the safety and compatibility of simultaneous co-use have not yet been evaluated. This technical compatibility study aimed to assess whether REN operation affects CGM performance or interferes with glucose measurement integrity in diabetic adults. Methods: Twenty-one adults with diabetes using Dexcom G6/G7 or FreeStyle Libre 2/3 participated in a single-arm interventional study. During a 45 min session, participants operated the REN and CGM devices simultaneously on their smartphones, and the REN device was paused three times to compare CGM readings between REN ON and RED OFF conditions. The primary outcome was the mean absolute relative difference (MARD_{REN ON/OFF}), evaluated against a prespecified 5% threshold. Statistical analysis included the Wilcoxon test, with subgroup analysis by the CGM device family. Results: The median MARD_{REN ON/OFF} across all participants was 1.61% (IQR 0.84–2.44%), significantly below the 5% threshold (p < 0.001). All participants achieved MARD_{REN ON/OFF} < 5%. Subgroup analyses were consistent: the median MARD_{REN ON/OFF} was 1.70% (IQR 0.90–2.45%) for Dexcom and 1.05% (IQR 0.83–1.50%) for Abbott. No technical interference, Bluetooth disruptions, missed data transmission, or adverse events were observed. Conclusions: Simultaneous use of Nerivio^® REN and CGM systems in adults with diabetes is compatible and safe, with no evidence of interference or significant deviations in glucose readings. These findings support the integrated and reliable use of REN and CGM wearables in adults with diabetes managing comorbid conditions. Full article

Background/Objectives: Pediatric migraine disrupts school performance and daily functioning. Concerns about medication overuse and limited efficacy highlight the need for non-pharmacologic treatments. The Nerivio remote electrical neuromodulation (REN) device, which is FDA-cleared for ages 8 and above, was evaluated in this study to assess real-world perceptions among patients in a pediatric neurology clinic. Methods: Patients aged 10–18 years who had used both acute medications and Nerivio completed two structured questionnaires, one reflecting on experiences with acute medication and one reflecting on experiences with acute REN treatment, assessing school and daily functioning, headache control, medication use, satisfaction, and preference. Descriptive statistics summarized the responses. Results: Twenty-four patients participated (91.7% female, mostly aged 13–18 years). Primary outcomes: Nerivio stopped headaches in 33.3% of patients and shortened them in 50.0%, with 41.7% reporting reduced medication use. Exploratory functional outcomes: Missed full school days were unchanged (3.8), partial absences decreased slightly (3.1 to 3.0, ~3%), limited-activity days declined from 3.5 to 2.7 (23%), and days with <50% functioning fell from 4.1 to 3.2 (22%). Preference favored Nerivio in 37.5%, medications in 20.8%, and both equally in 41.7%. Most patients (83.3%) wished to continue; 12.5% reported only mild, transient discomfort, and all continued treatment. Conclusions: This preliminary real-world study suggests that REN is feasible and beneficial in pediatric headache care. Primary outcomes demonstrated meaningful headache improvement, while exploratory measures suggested functional gains. REN reduced acute medication use and achieved high satisfaction, supporting its potential role as a patient-centered adjunct in pediatric headache management. Larger studies are needed to confirm these findings. Full article

Background/Objectives: Migraine affects 10% of adolescents and children. Typical school protocols in the USA require pharmacological medications to be administered by school nurses, often resulting in treatment delays or omissions when migraine attacks occur during school hours. The Remote Electrical Neuromodulation (REN) wearable is an FDA-cleared smartphone-controlled device delivering acute and preventive treatment of migraine attacks in patients aged 8 and above, allowing safe, effective, discreet, and independent usage. Methods: This retrospective study (NCT06180577) evaluates treatment patterns, barriers, and preferences among school-age students. REN users < 18 years old were invited to complete an online survey. Participants signed an assent form, and their parents/legal guardians signed an informed consent form. Results: 332 patients aged 7–17 (15.5 ± 2.1) participated (80.4% female). After being prescribed the REN wearable, the percentage of students who treated their headaches at school increased from 78.3% to 89.8%. Most participants (65.4%) treated with either REN standalone (38.0%) or in combination with medications (27.4%). Common barriers to treatment included the need to leave class for the nurse’s office (64.2%), concerns about standing out (42.2%), and one barrier unique to REN–permission needed to use a smartphone in class (22.9%). The most common reasons given for preferring REN treatment at school are the ability to avoid going to the nurse’s office (42.5%) and to treat discreetly (39.2%). Conclusions: This study underscores the challenges of managing migraine at school while suggesting the importance of the REN wearable as a discreet and independently used first-line treatment for children and adolescents. Full article